SavedAdd your journal

Journals / Türk Hijyen ve Deneysel Biyoloji Dergisi / 2017 / Cilt: 74 - Sayı: 2

Pharmacogenomics in lung cancer treatment

Akciğer kanseri tedavisinde farmakogenomik

Demet CANSARAN-DUMAN
Nil KILIÇ
Pages
175–184
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Patient-specific pharmacogenetic applications in lung carcinoma treatment and their effects on prognostic of disease were reviewed in this study

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Lung carcinoma is the most common cause of cancer-related death in men among other cancer types in last years.
📊
Key Findings & Data:The most recent and significant step in the treatment of the disease is the determination of the human genome structure and understanding of tumor biology.
💡
Conclusion & Impact:Patient-specific pharmacogenetic applications in lung carcinoma treatment and their effects on prognostic of disease were reviewed in this study
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Lung carcinoma is the most common cause of cancer-related death in men among other cancer types in last years. The most recent and significant step in the treatment of the disease is the determination of the human genome structure and understanding of tumor biology. Pharmacogenomics examines tumordependent gene mutations to determine in which patient the drug will be more effective. Personalized treatments that are specified directly to disease by using pharmacogenomics methods are applied to cure patients with minimum side effects. Also, determining sensitivity of drug against tumor by examining gene mutations in patients plays a crucial role in selection and outcome of treatment. Patient-specific pharmacogenetic applications in lung carcinoma treatment and their effects on prognostic of disease were reviewed in this study

Özet

Günümüzde akciğer kanseri erkeklerde en sık rastlanan ve ölümle sonuçlanan kanser tipleri arasında birinci sırayı almaktadır. Hastalığın tedavisine yönelik çalışmalarda en güncel ve önemli ivme insan genom yapısının belirlenmesi ve tümör biyolojisinin anlaşılması ile olmuştur. Farmakogenomik, tümör bağımlı gen mutasyonlarını inceleyerek ilacın hangi hastada hangi oranda daha etkili olacağını belirler. Farmakogenomik'e dayanan yöntemler ile direkt hastalığa yönelik kişiye spesifik tedavi yöntemleri uygulanarak en az yan etki ile hastayı iyileştirme yoluna gidilmektedir. Bunun yanında kişilerdeki gen mutasyonları detaylı incelenerek tümöre karşı ilaç duyarlılığının belirlenebilmesi tedavi seçiminde ve sonucunda çok önemli rol oynamıştır. Bu derleme kapsamında akciğer kanserinin tedavisinde hastaya özel tedavi yöntemine dayalı farmakogenomik uygulamaları ve hastalığın seyrine etkisi araştırılmıştır

🔖

Cite This Article

CANSARAN-DUMAN, D., KILIÇ, N. (2022). Pharmacogenomics in lung cancer treatment. Türk Hijyen ve Deneysel Biyoloji Dergisi, Cilt: 74 - Sayı: 2, 175–184. https://ajindex.com/articles/625002

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Vogel F. Moderne probleme der humangenetik. Ergeb Inn Med Kinderheilkd, 1959; 12: 52–125
  2. Meyer UA. Pharmacogenetics five decades of therapeutic lessons from genetic diversity. Nat Rev Genet, 2004; 5: 669-76
  3. Haydaroğlu A. Akciğer Kanserleri Tanı ve Tedavi. Ege Üniversitesi Basımevi, İzmir, 2000
  4. Yener NA, Apa DD, Akciğer Kanserinde Morfolojik Tanı ve Sınıflama. Trd Sem, 2014; 2: 281-9
  5. Huang YT, Heist RS, Chirieac LR, Lin X, Skaug V, Zienolddiny S, et al. Genome-wide analysis of survival in early-stage non-small-cell lung cancer. J Clin Oncol, 2009; 27: 2660-7
  6. Zhang Y, Martens JW, Yu JX, Jiang J, Sieuwerts AM, Smid M, et al. Copy number alterations that predict metastatic capability of human breast cancer. Cancer Res, 2009; 69: 3795-801
  7. Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res, 2010; 70(5): 2085-94
  8. Herbest RS, Lilenbaum R. Gemcitabine and vinorelbine cpmbinations in the treatment of nonsmall cell lung-cancer. J. Clin Oncol, 1999; 13: 1609
  9. Krug LM, Rubinstein L, Sadephi A, Group LCS. Phase II trials of vinorelbine and doc-etaxel in the treatment of advanced non-small cell lung cancer. Semin Oncol, 1999; 26: 24-6
  10. Sandler AB, Nemunaitis J, Denham C. Phase III trail of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol, 2000; 18: 120-2
  11. Gazdar AF. Personalized medicine and inhibition of EGFR signaling in lung cancer. N Engl J Med, 2009; 361: 1018-20
  12. Kratz JR, He J, Van Den Eeden SK, Zhu Z-H, Gao W, Pham P, et al. A practical molecular assay to predict survival in resected non- squamous, non-smallcell lung cancer: development and international validation studies. Lancet, 2012; 379: 823-32. 13. https://en.wikipedia.org/wiki/Imatinib (07.10.2016
  13. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor mutations in lung cancer. Nat Rev Cancer, 2007; 7(3): 161-81
  14. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 2004; 350: 2129- 39
  15. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical responses to gefitinib therapy. Scienc